The role of EZH2 in ocular diseases: a narrative review

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Varma R, Vajaranant TS, Burkemper B et al. Visual impairment and blindness in adults in the United States: demographic and geographic variations from 2015 to 2050. JAMA Ophthalmol. 134(7), 802–809 (2016).
  MedlineGoogle Scholar
• 2. Wang L, Zhu Z, Scheetz J, He M. Visual impairment and ten-year mortality: the Liwan Eye Study. Eye 35(8), 2173–2179 (2021).
  MedlineGoogle Scholar
• 3. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 23(7), 781–783 (2009).
  Medline CASGoogle Scholar
• 4. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 174(3), 341–348 (2006).
  MedlineGoogle Scholar
• 5. Vedschmidt SE, Stagner AM, Eagle RC Jr, Harocopos GJ, Dou Y, Rao RC. The targetable epigenetic tumor protein EZH2 is enriched in intraocular medulloepithelioma. Invest. Ophthalmol. Vis. Sci. 57(14), 6242–6246 (2016). • Demonstrates that EZH2 was highly expressed in moderately to poorly differentiated tumor cells.
  MedlineGoogle Scholar
• 6. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647(1–2), 21–29 (2008).
  Medline CASGoogle Scholar
• 7. Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J. Hematol. Oncol. 13(1), 104 (2020).
  Medline CASGoogle Scholar
• 8. Zhang J, Taylor RJ, La Torre A et al. EZH2 maintains retinal progenitor proliferation, transcriptional integrity, and the timing of late differentiation. Dev. Biol. 403(2), 128–138 (2015). •• Suggests that EZH2 plays a critical role in retinal progenitor proliferation, as well as regulating the timing of late differentiation.
  Medline CASGoogle Scholar
• 9. Jin B, Zhang P, Zou H et al. Verification of EZH2 as a druggable target in metastatic uveal melanoma. Mol. Cancer 19(1), 52 (2020).
  Medline CASGoogle Scholar
• 10. Cao J, Pontes KC, Heijkants RC et al. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target. J. Pathol. 245(4), 433–444 (2018).
  Medline CASGoogle Scholar
• 11. Khan M, Walters LL, Li Q et al. Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma. Lab. Invest. 95(11), 1278–1290 (2015). •• Shows that EZH2 might regulate human retinoblastoma tumorigenesis.
  Medline CASGoogle Scholar
• 12. Liao K, Cui Z, Zeng Y et al. Inhibition of enhancer of zeste homolog 2 prevents corneal myofibroblast transformation in vitro. Exp. Eye Res. 208, 108611 (2021).
  Medline CASGoogle Scholar
• 13. Zhang L, Wang L, Hu XB et al. MYPT1/PP1-mediated EZH2 dephosphorylation at S21 promotes epithelial-mesenchymal transition in fibrosis through control of multiple families of genes. Adv. Sci. (Weinh.) 9(14), e2105539 (2022).
  Medline CASGoogle Scholar
• 14. Thomas AA, Feng B, Chakrabarti S. ANRIL: a regulator of VEGF in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 58(1), 470–480 (2017).
  Medline CASGoogle Scholar
• 15. Di S, An X, Pang B et al. Yiqi Tongluo Fang could preventive and delayed development and formation of diabetic retinopathy through antioxidant and anti-inflammatory effects. Biomed. Pharmacother. 148, 112254 (2022).
  Medline CASGoogle Scholar
• 16. Mbefo M, Berger A, Schouwey K et al. Enhancer of zeste homolog 2 (EZH2) contributes to rod photoreceptor death process in several forms of retinal degeneration and its activity can serve as a biomarker for therapy efficacy. Int. J. Mol. Sci. 22(17), 9331 (2021). • Focuses on the role of EZH2 in the photoreceptor death process; demonstrates that EZH2 contributes to cell death and that the absence of the H3K27me3 mark may be a biomarker of the efficacy of EZH2 gene therapy.
  Medline CASGoogle Scholar
• 17. Wen X, Ding T, Li F et al. Interruption of aberrant chromatin looping is required for regenerating RB1 function and suppressing tumorigenesis. Commun. Biol. 5(1), 1036 (2022).
  Medline CASGoogle Scholar
• 18. Duraisamy AJ, Mishra M, Kowluru RA. Crosstalk between histone and DNA methylation in regulation of retinal matrix metalloproteinase-9 in diabetes. Invest. Ophthalmol. Vis. Sci. 58(14), 6440–6448 (2017).
  Medline CASGoogle Scholar
• 19. Zeng J, Zhang J, Sun Y et al. Targeting EZH2 for cancer therapy: from current progress to novel strategies. Eur. J. Med. Chem. 238, 114419 (2022).
  Medline CASGoogle Scholar
• 20. Völkel P, Dupret B, Le Bourhis X, Angrand PO. Diverse involvement of EZH2 in cancer epigenetics. Am. J. Transl. Res. 7(2), 175–193 (2015).
  MedlineGoogle Scholar
• 21. Yamaguchi H, Hung MC. Regulation and role of EZH2 in cancer. Cancer Res. Treat. 46(3), 209–222 (2014).
  Medline CASGoogle Scholar
• 22. Viré E, Brenner C, Deplus R et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078), 871–874 (2006).
  Medline CASGoogle Scholar
• 23. Kim E, Kim M, Woo DH et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23(6), 839–852 (2013).
  Medline CASGoogle Scholar
• 24. Fan T, Jiang S, Chung N et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol. Cancer Res. 9(4), 418–429 (2011).
  Medline CASGoogle Scholar
• 25. Hernandez AJ, Zovoilis A, Cifuentes-Rojas C, Han L, Bujisic B, Lee JT. B2 and ALU retrotransposons are self-cleaving ribozymes whose activity is enhanced by EZH2. Proc. Natl Acad. Sci. USA 117(1), 415–425 (2020).
  Medline CASGoogle Scholar
• 26. Tabbal H, Septier A, Mathieu M et al. EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness. Br. J. Cancer 121(5), 384–394 (2019).
  Medline CASGoogle Scholar
• 27. Rao RC, Tchedre KT, Malik MT et al. Dynamic patterns of histone lysine methylation in the developing retina. Invest. Ophthalmol. Vis. Sci. 51(12), 6784–6792 (2010).
  MedlineGoogle Scholar
• 28. Rapicavoli NA, Poth EM, Zhu H, Blackshaw S. The long noncoding RNA Six3OS acts in trans to regulate retinal development by modulating Six3 activity. Neural Dev. 6, 32 (2011).
  Medline CASGoogle Scholar
• 29. Aldiri I, Moore KB, Hutcheson DA, Zhang J, Vetter ML. Polycomb repressive complex PRC2 regulates Xenopus retina development downstream of Wnt/β-catenin signaling. Development 140(14), 2867–2878 (2013).
  Medline CASGoogle Scholar
• 30. Iida A, Iwagawa T, Kuribayashi H et al. Histone demethylase JMJD3 is required for the development of subsets of retinal bipolar cells. Proc. Natl Acad. Sci. USA 111(10), 3751–3756 (2014).
  Medline CASGoogle Scholar
• 31. Iida A, Iwagawa T, Baba Y et al. Roles of histone H3K27 trimethylase Ezh2 in retinal proliferation and differentiation. Dev. Neurobiol. 75(9), 947–960 (2015). •• Fouses on the influence of EZH2 knockout in retinal proliferation and differentiation.
  Medline CASGoogle Scholar
• 32. Watanabe S, Murakami A. Regulation of retinal development via the epigenetic modification of histone H3. Adv. Exp. Med. Biol. 854, 635–641 (2016).
  Medline CASGoogle Scholar
• 33. Fujimura N, Kuzelova A, Ebert A et al. Polycomb repression complex 2 is required for the maintenance of retinal progenitor cells and balanced retinal differentiation. Dev. Biol. 433(1), 47–60 (2018).
  Medline CASGoogle Scholar
• 34. Andrews D, Oliviero G, De Chiara L et al. Unravelling the transcriptional responses of TGF-β: Smad3 and EZH2 constitute a regulatory switch that controls neuroretinal epithelial cell fate specification. FASEB J. 33(5), 6667–6681 (2019).
  Medline CASGoogle Scholar
• 35. Ben-Yosef T. Inherited retinal diseases. Int. J. Mol. Sci. 23(21), 13467 (2022).
  MedlineGoogle Scholar
• 36. Zheng S, Xiao L, Liu Y et al. DZNep inhibits H3K27me3 deposition and delays retinal degeneration in the rd1 mice. Cell Death Dis. 9(3), 310 (2018).
  MedlineGoogle Scholar
• 37. Ueno K, Iwagawa T, Kuribayashi H et al. Transition of differential histone H3 methylation in photoreceptors and other retinal cells during retinal differentiation. Sci. Rep. 6, 29264 (2016).
  Medline CASGoogle Scholar
• 38. Yan N, Cheng L, Cho K et al. Postnatal onset of retinal degeneration by loss of embryonic Ezh2 repression of Six1. Sci. Rep. 6, 33887 (2016).
  Medline CASGoogle Scholar
• 39. Italiano A, Soria JC, Toulmonde M et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 19(5), 649–659 (2018).
  Medline CASGoogle Scholar
• 40. Morschhauser F, Tilly H, Chaidos A et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21(11), 1433–1442 (2020).
  Medline CASGoogle Scholar
• 41. Gounder M, Schöffski P, Jones RL et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 21(11), 1423–1432 (2020).
  Medline CASGoogle Scholar
• 42. Song Y, Liu Y, Li ZM et al. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol. 9(7), e493–e503 (2022).
  Medline CASGoogle Scholar
• 43. Izutsu K, Ando K, Nishikori M et al. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 112(9), 3627–3635 (2021).
  Medline CASGoogle Scholar
• 44. Vaswani RG, Gehling VS, Dakin LA et al. Identification of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-cell lymphomas. J. Med. Chem. 59(21), 9928–9941 (2016).
  Medline CASGoogle Scholar
• 45. Yap TA, Winter JN, Giulino-Roth L et al. Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin. Cancer Res. 25(24), 7331–7339 (2019).
  Medline CASGoogle Scholar
• 46. Munakata W, Shirasugi Y, Tobinai K et al. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer Sci. 112(3), 1123–1131 (2021).
  Medline CASGoogle Scholar
• 47. Zauderer MG, Szlosarek PW, Le Moulec S et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 23(6), 758–767 (2022).
  Medline CASGoogle Scholar
• 48. Lu Q, Zhao N, Zha G, Wang H, Tong Q, Xin S. LncRNA HOXA11-AS exerts oncogenic functions by repressing p21 and miR-124 in uveal melanoma. DNA Cell Biol. 36(10), 837–844 (2017).
  Medline CASGoogle Scholar
• 49. Li Y, Zhang M, Feng H, Mahati S. The tumorigenic properties of EZH2 are mediated by miR-26a in uveal melanoma. Front. Mol. Biosci. 8, 713542 (2021).
  Medline CASGoogle Scholar
• 50. Zhang J, Liu G, Jin H et al. MicroRNA-137 targets EZH2 to exert suppressive functions in uveal melanoma via regulation of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition. J. BUON 26(1), 173–181 (2021).
  MedlineGoogle Scholar
• 51. Hou C, Xiao L, Ren X et al. EZH2-mediated H3K27me3 is a predictive biomarker and therapeutic target in uveal melanoma. Front. Genet. 13, 1013475 (2022).
  Medline CASGoogle Scholar
• 52. Zhao Y, Cheng Y, Qu Y. The role of EZH2 as a potential therapeutic target in retinoblastoma. Exp. Eye Res. 227, 109389 (2023). • Shows that a high level of EZH2 in retinoblastoma tissues was significantly associated with poor overall survival. Inhibition of EZH2 is a potential target for anti-retinoblastoma treatment.
  Medline CASGoogle Scholar
• 53. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118(9), 1881–1885 (2011).
  MedlineGoogle Scholar
• 54. Smit KN, Jager MJ, De Klein A, Kiliç E. Uveal melanoma: towards a molecular understanding. Prog. Retin. Eye Res. 75, 100800 (2020).
  MedlineGoogle Scholar
• 55. Cheng Y, Li Y, Huang X, Wei W, Qu Y. Expression of EZH2 in uveal melanomas patients and associations with prognosis. Oncotarget 8(44), 76423–76431 (2017).
  MedlineGoogle Scholar
• 56. Wu X, Yuan Y, Ma R, Xu B, Zhang R. lncRNA SNHG7 affects malignant tumor behaviors through downregulation of EZH2 in uveal melanoma cell lines. Oncol. Lett. 19(2), 1505–1515 (2020).
  Medline CASGoogle Scholar
• 57. Chen X, He D, Dong XD et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 54(3), 2248–2256 (2013).
  Medline CASGoogle Scholar
• 58. Rossi E, Schinzari G, Maiorano BA et al. Conjunctival melanoma: genetic and epigenetic insights of a distinct type of melanoma. Int J Mol Sci 20(21), 5447 (2019).
  Medline CASGoogle Scholar
• 59. Mudhar HS, Salvi SS, Pissaloux D, De La Fouchardiere A. Single time frame overview of the genetic changes in conjunctival melanoma from intraepithelial disease to invasive melanoma: a study of 4 exenteration specimens illustrating the potential role of cyclin D1. Ocul. Oncol. Pathol. 8(1), 52–63 (2022).
  MedlineGoogle Scholar
• 60. Kaewkhaw R, Rojanaporn D. Retinoblastoma: etiology, modeling, and treatment. Cancers (Basel) 12(8), 2304 (2020).
  Medline CASGoogle Scholar
• 61. Fabian ID, Onadim Z, Karaa E et al. The management of retinoblastoma. Oncogene 37(12), 1551–1560 (2018).
  Medline CASGoogle Scholar
• 62. Dimaras H, Corson TW, Cobrinik D et al. Retinoblastoma. Nat. Rev. Dis. Primers 1, 15021 (2015).
  MedlineGoogle Scholar
• 63. Ishak CA, Marshall AE, Passos DT et al. An RB–EZH2 complex mediates silencing of repetitive DNA sequences. Mol. Cell 64(6), 1074–1087 (2016).
  Medline CASGoogle Scholar
• 64. Lei Q, Shen F, Wu J, Zhang W, Wang J, Zhang L. MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2. Oncol. Rep. 32(1), 261–269 (2014).
  Medline CASGoogle Scholar
• 65. Saunders T, Margo CE. Intraocular medulloepithelioma. Arch. Pathol. Lab. Med. 136(2), 212–216 (2012).
  Medline CASGoogle Scholar
• 66. Edward DP, Alkatan H, Rafiq Q et al. MicroRNA profiling in intraocular medulloepitheliomas. PLOS ONE 10(3), e0121706 (2015).
  MedlineGoogle Scholar
• 67. Fini ME. Keratocyte and fibroblast phenotypes in the repairing cornea. Prog. Retin. Eye Res. 18(4), 529–551 (1999).
  Medline CASGoogle Scholar
• 68. Wilson SE. Corneal wound healing. Exp. Eye Res. 197, 108089 (2020).
  Medline CASGoogle Scholar
• 69. Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. Prog. Retin. Eye Res. 49, 17–45 (2015).
  Medline CASGoogle Scholar
• 70. Kamil S, Mohan RR. Corneal stromal wound healing: major regulators and therapeutic targets. Ocul. Surf. 19, 290–306 (2021).
  MedlineGoogle Scholar
• 71. Zhao X, Song W, Chen Y, Liu S, Ren L. Collagen-based materials combined with microRNA for repairing cornea wounds and inhibiting scar formation. Biomater. Sci. 7(1), 51–62 (2018).
  MedlineGoogle Scholar
• 72. Shu DY, Lovicu FJ. Myofibroblast transdifferentiation: the dark force in ocular wound healing and fibrosis. Prog. Retin. Eye Res. 60, 44–65 (2017).
  MedlineGoogle Scholar
• 73. Myrna KE, Pot SA, Murphy CJ. Meet the corneal myofibroblast: the role of myofibroblast transformation in corneal wound healing and pathology. Vet. Ophthalmol. 12(Suppl. 1), 25–27 (2009).
  MedlineGoogle Scholar
• 74. Wilson SE. Corneal myofibroblasts and fibrosis. Exp. Eye Res. 201, 108272 (2020).
  Medline CASGoogle Scholar
• 75. Wan S-S, Pan Y-M, Yang W-J, Rao Z-Q, Yang Y-N. Inhibition of EZH2 alleviates angiogenesis in a model of corneal neovascularization by blocking FoxO3a-mediated oxidative stress. FASEB J. 34(8), 10168–10181 (2020).
  Medline CASGoogle Scholar
• 76. Thompson J, Lakhani N. Cataracts. Prim. Care 42(3), 409–423 (2015).
  MedlineGoogle Scholar
• 77. Liu YC, Wilkins M, Kim T, Malyugin B, Mehta JS. Cataracts. Lancet 390(10094), 600–612 (2017).
  MedlineGoogle Scholar
• 78. Gao M, Huang Y, Wang L et al. HSF4 regulates lens fiber cell differentiation by activating p53 and its downstream regulators. Cell Death Dis. 8(10), e3082 (2017).
  MedlineGoogle Scholar
• 79. Mou L, Xu JY, Li W et al. Identification of vimentin as a novel target of HSF4 in lens development and cataract by proteomic analysis. Invest. Ophthalmol. Vis. Sci. 51(1), 396–404 (2010).
  MedlineGoogle Scholar
• 80. Cui X, Du C, Wan S et al. Deficiency of heat shock factor 4 promotes lens epithelial cell senescence through upregulating p21^cip1 expression. Biochim. Biophys. Acta Mol. Basis Dis. 1867(11), 166233 (2021).
  Medline CASGoogle Scholar
• 81. Lee CM, Afshari NA. The global state of cataract blindness. Curr. Opin. Ophthalmol. 28(1), 98–103 (2017).
  MedlineGoogle Scholar
• 82. Wormstone IM, Wang L, Liu CS. Posterior capsule opacification. Exp. Eye Res. 88(2), 257–269 (2009).
  Medline CASGoogle Scholar
• 83. Wormstone IM, Eldred JA. Experimental models for posterior capsule opacification research. Exp. Eye Res. 142, 2–12 (2016).
  Medline CASGoogle Scholar
• 84. Wormstone IM, Wormstone YM, Smith AJO, Eldred JA. Posterior capsule opacification: what's in the bag? Prog. Retin. Eye Res. 82, 100905 (2021).
  Medline CASGoogle Scholar
• 85. Dong N, Xu B, Xu J. EGF-Mediated overexpression of Myc attenuates miR-26b by recruiting HDAC3 to induce epithelial–mesenchymal transition of lens epithelial cells. Biomed. Res. Int. 2018, 7148023 (2018).
  MedlineGoogle Scholar
• 86. Imaizumi T, Kurosaka D, Tanaka U, Sakai D, Fukuda K, Sanbe A. Topical administration of a ROCK inhibitor prevents anterior subcapsular cataract induced by UV-B irradiation. Exp. Eye Res. 181, 145–149 (2019).
  Medline CASGoogle Scholar
• 87. Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res. 31(2), 152–181 (2012).
  Medline CASGoogle Scholar
• 88. Fry LE, Fahy E, Chrysostomou V et al. The coma in glaucoma: retinal ganglion cell dysfunction and recovery. Prog. Retin. Eye Res. 65, 77–92 (2018).
  MedlineGoogle Scholar
• 89. Xiao L, Hou C, Cheng L, Zheng S, Zhao L, Yan N. DZNep protects against retinal ganglion cell death in an NMDA-induced mouse model of retinal degeneration. Exp. Eye Res. 212, 108785 (2021).
  Medline CASGoogle Scholar
• 90. Cheng L, Wong LJ, Yan N et al. Ezh2 does not mediate retinal ganglion cell homeostasis or their susceptibility to injury. PLOS ONE 13(2), e0191853 (2018).
  MedlineGoogle Scholar
• 91. Zhou RR, Li HB, You QS et al. Silencing of GAS5 alleviates glaucoma in rat models by reducing retinal ganglion cell apoptosis. Hum. Gene Ther. 30(12), 1505–1519 (2019).
  Medline CASGoogle Scholar
• 92. Zhang N, Cao W, He X, Xing Y, Yang N. Long non-coding RNAs in retinal ganglion cell apoptosis. Cell. Mol. Neurobiol. 43(2), 561–574 (2023).
  Medline CASGoogle Scholar
• 93. Kowluru RA, Mohammad G, Dos Santos JM, Zhong Q. Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes 60(11), 3023–3033 (2011).
  Medline CASGoogle Scholar
• 94. Huang Y, Yu SH, Zhen WX et al. Tanshinone I, a new EZH2 inhibitor restricts normal and malignant hematopoiesis through upregulation of MMP9 and ABCG2. Theranostics 11(14), 6891–6904 (2021).
  Medline CASGoogle Scholar
• 95. Delgado-Olguín P, Dang LT, He D et al. Ezh2-mediated repression of a transcriptional pathway upstream of Mmp9 maintains integrity of the developing vasculature. Development 141(23), 4610–4617 (2014).
  Medline CASGoogle Scholar
• 96. Song Z, Wu W, Chen M et al. Long noncoding RNA ANRIL supports proliferation of adult T-cell leukemia cells through cooperation with EZH2. J. Virol. 92(24), e00909–18 (2018).
  Medline CASGoogle Scholar
• 97. Yang LH, Du P, Liu W et al. LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN. Neoplasma 68(4), 788–797 (2021).
  Medline CASGoogle Scholar
• 98. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 22(1), 1–29 (2003).
  Medline CASGoogle Scholar
• 99. Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye 28(5), 510–520 (2014).
  Medline CASGoogle Scholar
• 100. Yang Y, Liu Y, Li Y et al. MicroRNA-15b targets VEGF and inhibits angiogenesis in proliferative diabetic retinopathy. J. Clin. Endocrinol. Metab. 105(11), 3404–3415 (2020).
  MedlineGoogle Scholar
• 101. Wong TY, Cheung CM, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat. Rev. Dis. Primers 2, 16012 (2016).
  MedlineGoogle Scholar
• 102. Ruiz MA, Feng B, Chakrabarti S. Polycomb repressive complex 2 regulates miR-200b in retinal endothelial cells: potential relevance in diabetic retinopathy. PLOS ONE 10(4), e0123987 (2015).
  MedlineGoogle Scholar
• 103. Biswas S, Thomas AA, Feng B et al. MALAT1 and HOTAIR – key epigenetic regulators in diabetic retinopathy. Diabetes 67(Suppl. 1), 240-OR (2018).
  Google Scholar
• 104. Di S, An X, Pang B et al. Yiqi Tongluo Fang could preventive and delayed development and formation of diabetic retinopathy through antioxidant and anti-inflammatory effects. Biomed. Pharmacother. 148, 112254 (2022).
  Medline CASGoogle Scholar
• 105. Olivares AM, Jelcick AS, Reinecke J et al. Multimodal regulation orchestrates normal and complex disease states in the retina. Sci. Rep. 7(1), 690 (2017).
  Medline CASGoogle Scholar
• 106. Peng Y, Liao K, Tan F et al. Suppression of EZH2 inhibits TGF-β1-induced EMT in human retinal pigment epithelial cells. Exp. Eye Res. 222, 109158 (2022).
  Medline CASGoogle Scholar
• 107. Lee HE, Ayarpadikannan S, Kim HS. Role of transposable elements in genomic rearrangement, evolution, gene regulation and epigenetics in primates. Genes Genet. Syst. 90(5), 245–257 (2015).
  Medline CASGoogle Scholar
• 108. Kaneko H, Dridi S, Tarallo V et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471(7338), 325–330 (2011).
  Medline CASGoogle Scholar
• 109. Tarallo V, Hirano Y, Gelfand BD et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149(4), 847–859 (2012).
  Medline CASGoogle Scholar
• 110. Gelfand BD, Wright CB, Kim Y et al. Iron toxicity in the retina requires Alu RNA and the NLRP3 inflammasome. Cell Rep. 11(11), 1686–1693 (2015).
  Medline CASGoogle Scholar
• 111. Zhu S, Liu M, Zhu F, Yu X, Wen J, Li C. Targeting EZH2 prevents the occurrence and mitigates the development of Sjögren’s syndrome in mice. Int. Immunopharmacol. 110, 109073 (2022).
  Medline CASGoogle Scholar
• 112. He C, Yang Y, Chen Z et al. EZH2 promotes T follicular helper cell differentiation through enhancing STAT3 phosphorylation in patients with primary Sjögren’s syndrome. Front. Immunol. 13, 922871 (2022).
  Medline CASGoogle Scholar
• 113. Katoh M. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy. Epigenomics 8(2), 285–305 (2016).
  CASGoogle Scholar